If the BCR signal pathway is not the dominant driving the growth of CD5-positive DLBCL, it is plausible that an alternative signaling cascade may be contributing to their proliferation and survival. Further research is needed to elucidate the specific signaling pathways that govern the biology of CD5-positive DLBCL, which could pave the way for the development of targeted therapies tailored to this distinct subgroup of patients. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.